Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 2/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9749127 | 0.90 | ATM (0.56) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL19859590 | 0.90 | ATM (0.56) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL3202235 | 0.90 | ATM (0.56) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL9937088 | 0.87 | TRPM8 (0.55) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL6044625 | 0.87 | PSMB1 (0.58) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL6044628 | 0.87 | PSMB1 (0.58) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL6044396 | 0.87 | PSMB1 (0.58) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL9937089 | 0.87 | TRPM8 (0.55) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL6044481 | 0.86 | ATM (0.52) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL8682643 | 0.86 | ATM (0.52) | ATMELANETRPM8CTSKCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | ATM 856/4885ELANE 1284/4885TRPM8 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.